487 related articles for article (PubMed ID: 12588182)
1. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL
Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells.
Reilly CA; Ehlhardt WJ; Jackson DA; Kulanthaivel P; Mutlib AE; Espina RJ; Moody DE; Crouch DJ; Yost GS
Chem Res Toxicol; 2003 Mar; 16(3):336-49. PubMed ID: 12641434
[TBL] [Abstract][Full Text] [Related]
3. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.
Jorga K; Fotteler B; Heizmann P; Gasser R
Br J Clin Pharmacol; 1999 Oct; 48(4):513-20. PubMed ID: 10583021
[TBL] [Abstract][Full Text] [Related]
5. In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity.
Sun Q; Zhu R; Foss FW; Macdonald TL
Chem Res Toxicol; 2008 Mar; 21(3):711-9. PubMed ID: 18298092
[TBL] [Abstract][Full Text] [Related]
6. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
[TBL] [Abstract][Full Text] [Related]
7. One-electron oxidation of diclofenac by human cytochrome P450s as a potential bioactivation mechanism for formation of 2'-(glutathion-S-yl)-deschloro-diclofenac.
Boerma JS; Vermeulen NP; Commandeur JN
Chem Biol Interact; 2014 Jan; 207():32-40. PubMed ID: 24246759
[TBL] [Abstract][Full Text] [Related]
8. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.
Haasio K; Nissinen E; Sopanen L; Heinonen EH
J Neural Transm (Vienna); 2002 Nov; 109(11):1391-401. PubMed ID: 12454735
[TBL] [Abstract][Full Text] [Related]
9. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Korlipara LV; Cooper JM; Schapira AH
Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
[TBL] [Abstract][Full Text] [Related]
10. In vitro nimesulide studies toward understanding idiosyncratic hepatotoxicity: diiminoquinone formation and conjugation.
Li F; Chordia MD; Huang T; Macdonald TL
Chem Res Toxicol; 2009 Jan; 22(1):72-80. PubMed ID: 19053182
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
Benabou R; Waters C
Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105
[TBL] [Abstract][Full Text] [Related]
12. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.
Kassahun K; Pearson PG; Tang W; McIntosh I; Leung K; Elmore C; Dean D; Wang R; Doss G; Baillie TA
Chem Res Toxicol; 2001 Jan; 14(1):62-70. PubMed ID: 11170509
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite.
Mahajan MK; Uttamsingh V; Daniels JS; Gan LS; LeDuc BW; Williams DA
Drug Metab Dispos; 2011 Apr; 39(4):693-702. PubMed ID: 21177487
[TBL] [Abstract][Full Text] [Related]
14. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.
Grünig D; Felser A; Bouitbir J; Krähenbühl S
Toxicol In Vitro; 2017 Aug; 42():337-347. PubMed ID: 28526448
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
[TBL] [Abstract][Full Text] [Related]
16. In vitro metabolic activation of thiabendazole via 5-hydroxythiabendazole: identification of a glutathione conjugate of 5-hydroxythiabendazole.
Dalvie D; Smith E; Deese A; Bowlin S
Drug Metab Dispos; 2006 Apr; 34(4):709-17. PubMed ID: 16434547
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats.
Chen Q; Doss GA; Tung EC; Liu W; Tang YS; Braun MP; Didolkar V; Strauss JR; Wang RW; Stearns RA; Evans DC; Baillie TA; Tang W
Drug Metab Dispos; 2006 Jan; 34(1):145-51. PubMed ID: 16251255
[TBL] [Abstract][Full Text] [Related]
18. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
Borges N
Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
[TBL] [Abstract][Full Text] [Related]
19. Bioactivation of glafenine by human liver microsomes and peroxidases: identification of electrophilic iminoquinone species and GSH conjugates.
Wen B; Moore DJ
Drug Metab Dispos; 2011 Sep; 39(9):1511-21. PubMed ID: 21628497
[TBL] [Abstract][Full Text] [Related]
20. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
Lautala P; Kivimaa M; Salomies H; Elovaara E; Taskinen J
Pharm Res; 1997 Oct; 14(10):1444-8. PubMed ID: 9358559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
